Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…